NORFLEX
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Nov 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORFLEX is an oral extended-release tablet approved in 1959 for muscle relaxation. The generic name and mechanism of action are not specified in available data, but the product is classified as a traditional small-molecule NDA. It serves patients requiring chronic musculoskeletal pain management.
LOE Approaching
As LOE approaches, the brand team is likely consolidating to protect revenue and manage generic transition; headcount and investment are at risk.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NORFLEX as LOE approaches offers limited career upside; the role is primarily defensive and focused on margin protection through generics management. Opportunities exist in managed-care negotiations and cost-containment strategy, but headcount and budget are contracting.
Brand ManagerField Sales Representative
Worked on NORFLEX at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.